<p>传奇生物（NASDAQ:LEGN - 获取免费报告）在周三发布的一份报告中，皇家银行的研究分析师将其目标价从 66.00 美元下调至 62.00 美元，Benzinga 报道。该券商目前对该股票给予 “跑赢大盘” 的评级。皇家银行的目标价暗示该公司当前价格有 209.77% 的潜在上涨空间。</p>
<p>获取 <strong>传奇生物</strong> 的提醒：</p>
<ul>
<li>CPI 数据引发生物科技股票反弹</li>
</ul>
<p>其他几位研究分析师最近也对 LEGN 发表了评论。雷蒙德·詹姆斯金融公司在 2 月 23 日的研究报告中重申了对传奇生物股票的 “跑赢大盘” 评级。罗斯柴尔德与红烧公司将传奇生物的评级从 “买入” 下调至 “中性”，并设定了 24.00 美元的目标价。在 2 月 12 日的报告中，瑞银集团将传奇生物的目标价从 54.00 美元下调至 48.00 美元，并在 12 月 8 日的报告中对该股票给予 “买入” 评级。Truist Financial 在周二的报告中设定了 70.00 美元的目标价。最后，TD Cowen 在 1 月 22 日的研究报告中重申了 “持有” 评级，并将传奇生物的目标价下调至 21.00 美元（从 62.00 美元下调）。共有 11 位研究分析师对该股票给予 “买入” 评级，4 位给予 “持有” 评级，1 位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 58.38 美元。</p>
<p><strong>查看我们对传奇生物的最新分析</strong></p>
<h2>传奇生物股票上涨 2.3%</h2>
<ul>
<li>为什么传奇生物股票正经历最佳月份</li>
</ul>
<p>NASDAQ:LEGN 在周三的交易时段上涨了 0.46 美元，达到 20.02 美元。该股票的交易量为 249,786 股，而其平均交易量为 2,559,654 股。该公司的债务与股本比率为 0.17，流动比率为 2.86，速动比率为 2.80。传奇生物的 12 个月低点为 16.24 美元，12 个月高点为 45.30 美元。该公司的 50 日移动平均线为 19.51 美元，200 日移动平均线为 26.47 美元。该股票的市值为 37 亿美元，市盈率为-30.77，贝塔值为 0.07。</p>
<p>传奇生物（NASDAQ:LEGN - 获取免费报告）最近在 3 月 10 日发布了季度财报。该公司报告季度每股收益为 0.01 美元，超出分析师一致预期的-0.17 美元，超出幅度为 0.18 美元。该公司在季度内的收入为 3.063 亿美金，而一致预期为 3.102 亿美金。传奇生物的净利润率为-26.37%，股本回报率为-24.47%。该公司的季度收入同比增长 64.2%。在去年同期，该公司报告的每股收益为 0.07 美元。平均而言，股票分析师预计传奇生物在本年度的每股收益将为-1.31 美元。</p>
<h2>对传奇生物的对冲基金看法</h2>
<p>对冲基金和其他机构投资者最近修改了对该公司的持股。Resona Asset Management Co. Ltd.在第二季度增持了传奇生物 25.5% 的股份。Resona Asset Management Co. Ltd.目前拥有 21,901 股该公司的股票，价值 775,000 美元，此前在上个季度购买了 4,451 股。三菱 UFJ 资产管理公司在第二季度增持了传奇生物 34.4% 的股份。三菱 UFJ 资产管理公司目前拥有 74,751 股该公司的股票，价值 2,653,000 美元，此前在上个季度购买了 19,141 股。Campbell &amp; CO 投资顾问公司在第二季度购买了传奇生物的新股份，价值 721,000 美元。PNC 金融服务集团在第二季度增持了传奇生物 41.1% 的股份。PNC 金融服务集团目前拥有 6,936 股该公司的股票，价值 246,000 美元，此前在上个季度购买了 2,020 股。最后，Candriam S.C.A.在第二季度增持了传奇生物 18.0% 的股份。Candriam S.C.A.目前拥有 261,815 股该公司的股票，价值 9,292,000 美元，此前在该期间购买了 39,983 股。对冲基金和其他机构投资者持有该公司 70.89% 的股份。</p>
<h2>关于传奇生物</h2>
<p>（获取免费报告）</p>
<p>传奇生物 NASDAQ: LEGN 是一家商业阶段的生物制药公司，专注于开发和商业化用于肿瘤治疗的嵌合抗原受体 T 细胞（CAR-T）疗法。公司总部位于新泽西州萨默塞特，在上海设有研发业务，利用全球基础设施推进创新的细胞疗法。传奇生物通过与强生的子公司 Janssen Biotech 的合作，追求战略合作以扩大其影响力。</p>
<p>公司的主要资产，ciltacabtagene autoleucel（商业名称为 Carvykti），是一种针对 B 细胞成熟抗原（BCMA）的 CAR-T 疗法，用于治疗复发或难治性多发性骨髓瘤。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们更看好的股票比传奇生物更好</li>
<li>华尔街害怕的黄金图表……</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>埃隆·马斯克已经让我成为 “富有的人”</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>1,500 家银行刚刚把你的银行账户交给了美联储</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEVHTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在传奇生物吗？</h2>
<p>在考虑传奇生物之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而传奇生物并不在名单上。</p>
<p>虽然传奇生物目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

传奇生物

2 倍做多纳斯达克生物技术 ETF - ProShares

IBBQ

<p>加拿大皇家银行已将传奇生物（NASDAQ:LEGN）的目标股价从 66.00 美元下调至 62.00 美元，同时维持 “跑赢大盘” 的评级。这表明从当前价格来看，潜在上涨幅度为 209.77%。其他分析师的观点各异，有些维持买入评级，而另一些则下调了目标价。目前，传奇生物的股票交易价格为 20.02 美元，市值为 37 亿美元，净利润率为负 26.37%。该公司报告的季度收入同比增长 64.2%</p>

<p>Legend Biotech (NASDAQ:LEGN - Get Free Report) had its price objective dropped by research analysts at Royal Bank Of Canada from $66.00 to $62.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an &#34;outperform&#34; rating on the stock. Royal Bank Of Canada's target price would suggest a potential upside of 209.77% from the company's current price.</p>
<div class="lb-trans"><p>传奇生物（NASDAQ:LEGN - 获取免费报告）在周三发布的一份报告中，皇家银行的研究分析师将其目标价从 66.00 美元下调至 62.00 美元，Benzinga 报道。该券商目前对该股票给予 “跑赢大盘” 的评级。皇家银行的目标价暗示该公司当前价格有 209.77% 的潜在上涨空间。</p>
</div><p>Get <strong>Legend Biotech</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>传奇生物</strong> 的提醒：</p>
</div><ul>
<li>CPI Data Sparks Rally in Biotech Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>CPI 数据引发生物科技股票反弹</li>
</ul>
</div><p>Several other research analysts also recently commented on LEGN. Raymond James Financial restated an &#34;outperform&#34; rating on shares of Legend Biotech in a research report on Monday, February 23rd. Rothschild &amp; Co Redburn cut Legend Biotech from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $24.00 target price on the stock. in a report on Thursday, February 12th. UBS Group dropped their target price on shares of Legend Biotech from $54.00 to $48.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, December 8th. Truist Financial set a $70.00 price target on Legend Biotech in a report on Tuesday. Finally, TD Cowen reiterated a &#34;hold&#34; rating and issued a $21.00 price objective (down from $62.00) on shares of Legend Biotech in a research note on Thursday, January 22nd. Eleven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $58.38.</p>
<div class="lb-trans"><p>其他几位研究分析师最近也对 LEGN 发表了评论。雷蒙德·詹姆斯金融公司在 2 月 23 日的研究报告中重申了对传奇生物股票的 “跑赢大盘” 评级。罗斯柴尔德与红烧公司将传奇生物的评级从 “买入” 下调至 “中性”，并设定了 24.00 美元的目标价。在 2 月 12 日的报告中，瑞银集团将传奇生物的目标价从 54.00 美元下调至 48.00 美元，并在 12 月 8 日的报告中对该股票给予 “买入” 评级。Truist Financial 在周二的报告中设定了 70.00 美元的目标价。最后，TD Cowen 在 1 月 22 日的研究报告中重申了 “持有” 评级，并将传奇生物的目标价下调至 21.00 美元（从 62.00 美元下调）。共有 11 位研究分析师对该股票给予 “买入” 评级，4 位给予 “持有” 评级，1 位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 58.38 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Legend Biotech</strong></p>
<div class="lb-trans"><p><strong>查看我们对传奇生物的最新分析</strong></p>
</div><h2>Legend Biotech Stock Up 2.3%</h2>
<div class="lb-trans"><h2>传奇生物股票上涨 2.3%</h2>
</div><ul>
<li>Why Legend Biotech Stock Is Having Its Best Month Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么传奇生物股票正经历最佳月份</li>
</ul>
</div><p>NASDAQ:LEGN traded up $0.46 during trading hours on Wednesday, reaching $20.02. 249,786 shares of the stock were exchanged, compared to its average volume of 2,559,654. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.86 and a quick ratio of 2.80. Legend Biotech has a twelve month low of $16.24 and a twelve month high of $45.30. The firm has a 50 day moving average of $19.51 and a 200 day moving average of $26.47. The stock has a market cap of $3.70 billion, a PE ratio of -30.77 and a beta of 0.07.</p>
<div class="lb-trans"><p>NASDAQ:LEGN 在周三的交易时段上涨了 0.46 美元，达到 20.02 美元。该股票的交易量为 249,786 股，而其平均交易量为 2,559,654 股。该公司的债务与股本比率为 0.17，流动比率为 2.86，速动比率为 2.80。传奇生物的 12 个月低点为 16.24 美元，12 个月高点为 45.30 美元。该公司的 50 日移动平均线为 19.51 美元，200 日移动平均线为 26.47 美元。该股票的市值为 37 亿美元，市盈率为-30.77，贝塔值为 0.07。</p>
</div><p>Legend Biotech (NASDAQ:LEGN - Get Free Report) last posted its quarterly earnings data on Tuesday, March 10th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.18. The company had revenue of $306.30 million during the quarter, compared to the consensus estimate of $310.21 million. Legend Biotech had a negative net margin of 26.37% and a negative return on equity of 24.47%. The company's quarterly revenue was up 64.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.07 EPS. On average, equities analysts expect that Legend Biotech will post -1.31 earnings per share for the current year.</p>
<div class="lb-trans"><p>传奇生物（NASDAQ:LEGN - 获取免费报告）最近在 3 月 10 日发布了季度财报。该公司报告季度每股收益为 0.01 美元，超出分析师一致预期的-0.17 美元，超出幅度为 0.18 美元。该公司在季度内的收入为 3.063 亿美金，而一致预期为 3.102 亿美金。传奇生物的净利润率为-26.37%，股本回报率为-24.47%。该公司的季度收入同比增长 64.2%。在去年同期，该公司报告的每股收益为 0.07 美元。平均而言，股票分析师预计传奇生物在本年度的每股收益将为-1.31 美元。</p>
</div><h2>Hedge Funds Weigh In On Legend Biotech</h2>
<div class="lb-trans"><h2>对传奇生物的对冲基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the business. Resona Asset Management Co. Ltd. boosted its position in Legend Biotech by 25.5% in the second quarter. Resona Asset Management Co. Ltd. now owns 21,901 shares of the company's stock worth $775,000 after purchasing an additional 4,451 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Legend Biotech by 34.4% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 74,751 shares of the company's stock valued at $2,653,000 after purchasing an additional 19,141 shares during the last quarter. Campbell &amp; CO Investment Adviser LLC bought a new stake in shares of Legend Biotech during the 2nd quarter worth $721,000. PNC Financial Services Group Inc. boosted its holdings in shares of Legend Biotech by 41.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 6,936 shares of the company's stock worth $246,000 after buying an additional 2,020 shares during the last quarter. Finally, Candriam S.C.A. grew its position in Legend Biotech by 18.0% during the second quarter. Candriam S.C.A. now owns 261,815 shares of the company's stock valued at $9,292,000 after buying an additional 39,983 shares during the period. Hedge funds and other institutional investors own 70.89% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近修改了对该公司的持股。Resona Asset Management Co. Ltd.在第二季度增持了传奇生物 25.5% 的股份。Resona Asset Management Co. Ltd.目前拥有 21,901 股该公司的股票，价值 775,000 美元，此前在上个季度购买了 4,451 股。三菱 UFJ 资产管理公司在第二季度增持了传奇生物 34.4% 的股份。三菱 UFJ 资产管理公司目前拥有 74,751 股该公司的股票，价值 2,653,000 美元，此前在上个季度购买了 19,141 股。Campbell &amp; CO 投资顾问公司在第二季度购买了传奇生物的新股份，价值 721,000 美元。PNC 金融服务集团在第二季度增持了传奇生物 41.1% 的股份。PNC 金融服务集团目前拥有 6,936 股该公司的股票，价值 246,000 美元，此前在上个季度购买了 2,020 股。最后，Candriam S.C.A.在第二季度增持了传奇生物 18.0% 的股份。Candriam S.C.A.目前拥有 261,815 股该公司的股票，价值 9,292,000 美元，此前在该期间购买了 39,983 股。对冲基金和其他机构投资者持有该公司 70.89% 的股份。</p>
</div><h2>About Legend Biotech</h2>
<div class="lb-trans"><h2>关于传奇生物</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Legend Biotech NASDAQ: LEGN is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson &amp; Johnson.</p>
<div class="lb-trans"><p>传奇生物 NASDAQ: LEGN 是一家商业阶段的生物制药公司，专注于开发和商业化用于肿瘤治疗的嵌合抗原受体 T 细胞（CAR-T）疗法。公司总部位于新泽西州萨默塞特，在上海设有研发业务，利用全球基础设施推进创新的细胞疗法。传奇生物通过与强生的子公司 Janssen Biotech 的合作，追求战略合作以扩大其影响力。</p>
</div><p>The company's lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.</p>
<div class="lb-trans"><p>公司的主要资产，ciltacabtagene autoleucel（商业名称为 Carvykti），是一种针对 B 细胞成熟抗原（BCMA）的 CAR-T 疗法，用于治疗复发或难治性多发性骨髓瘤。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Legend Biotech</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Elon Musk already made me a “wealthy man”</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>1,500 Banks Just Handed the Fed Your Bank Account</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比传奇生物更好</li>
<li>华尔街害怕的黄金图表……</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>埃隆·马斯克已经让我成为 “富有的人”</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>1,500 家银行刚刚把你的银行账户交给了美联储</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEVHTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=LEGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Legend Biotech Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在传奇生物吗？</h2>
</div><p>Before you consider Legend Biotech, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑传奇生物之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而传奇生物并不在名单上。</p>
</div><p>While Legend Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然传奇生物目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Royal Bank Of Canada Has Lowered Expectations for Legend Biotech (NASDAQ:LEGN) Stock Price

Market Beat

Invesco Nasdaq Biotechnology ETF

医药突破 ETF - ALPS

基因改革 ETF - ARK

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

加拿大皇家银行下调了对传奇生物（NASDAQ:LEGN）股票价格的预期